Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) Director David P. Hochman bought 10,000 shares of the stock in a transaction on Friday, November 18th. The stock was purchased at an average price of $7.00 per share, for a total transaction of $70,000.00. Following the completion of the purchase, the director now owns 456,100 shares of the company’s stock, valued at $3,192,700. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) traded down 2.6573% during mid-day trading on Tuesday, hitting $7.6414. The company had a trading volume of 1,067,219 shares. The firm’s 50 day moving average is $7.27 and its 200 day moving average is $4.60. The company’s market capitalization is $339.56 million. Corbus Pharmaceuticals Holdings Inc. has a 52 week low of $1.01 and a 52 week high of $10.78.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Milestone Group Inc. bought a new position in Corbus Pharmaceuticals Holdings during the third quarter worth $102,000. Bainco International Investors bought a new position in Corbus Pharmaceuticals Holdings during the third quarter worth $136,000. Bank of New York Mellon Corp bought a new position in Corbus Pharmaceuticals Holdings during the third quarter worth $155,000. Morgan Stanley raised its position in Corbus Pharmaceuticals Holdings by 12.4% in the third quarter. Morgan Stanley now owns 29,909 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 3,300 shares during the period. Finally, Northern Trust Corp raised its position in Corbus Pharmaceuticals Holdings by 41.0% in the third quarter. Northern Trust Corp now owns 45,436 shares of the biopharmaceutical company’s stock worth $309,000 after buying an additional 13,222 shares during the period. 25.47% of the stock is owned by institutional investors.

Several brokerages have issued reports on CRBP. Aegis restated a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research note on Sunday, August 21st. Cantor Fitzgerald restated a “buy” rating and issued a $17.00 target price on shares of Corbus Pharmaceuticals Holdings in a research note on Tuesday, November 15th. JMP Securities boosted their target price on Corbus Pharmaceuticals Holdings from $9.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, November 15th. Finally, Noble Financial restated a “buy” rating and issued a $19.00 target price on shares of Corbus Pharmaceuticals Holdings in a research note on Friday, November 11th.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.

5 Day Chart for NASDAQ:CRBP

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.